Heather Sheppard
YOU?
Author Swipe
View article: Figure S6 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S6 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S6 shows B7-H3.CAR T-cell expansion vs EPN cell target antigen density.
View article: Figure S17 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S17 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S17 shows effective control of PFA EPN xenografts by B7-H3.CAR T-cells in vivo.
View article: Figure S22 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S22 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S22 shows IHC evaluation of B7-H3 expression and CD3+ cell infiltration inside syngeneic ZFTA-RELA EPN tumors.
View article: Figure S15 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S15 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S15 shows increased inhibitory marker expression on B7-H3.CAR T-cells compared to HER2.CAR T-cells following repeated stimulation with 1425 cell line.
View article: Figure S1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S1 shows representative B7-H3 staining intensity scale.
View article: Figure S5 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S5 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S5 shows phenotypic characteristics of human B7-H3.CAR T-cells.
View article: Figure S21 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S21 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S21 shows IHC evaluation and quantification of immune cell infiltration inside syngeneic ZFTA-RELA EPN tumors.
View article: Figure S3 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S3 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S3 shows regulation of B7-H3 transcriptional activity by ZFTA-RELA oncogene.
View article: Figure S7 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S7 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S7 shows inverse correlation between B7-H3.CAR T-cell expansion and B7-H3 target antigen density.
View article: Figure S11 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S11 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S11 shows phenotypic characteristics of human HER2.CAR T-cells.
View article: Figure S13 legend1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S13 legend1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S13 legend
View article: Figure S19 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S19 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S19 shows successful infiltration of HER2.CAR T-cells inside 1425 EPN xenograft tumors.
View article: Figure S16 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S16 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S16 shows high potency but limited durability of B7-H3.CAR T-cells against ZFTA-RELA EPN xenograft tumors in vivo.
View article: Figure S9 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S9 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S9 shows Type 2 polarization of B7-H3.CAR T-cells over repetitive stimulation with EPN cells.
View article: Figure S10 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S10 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S10 shows increased CXCL10 secretion following repetitive stimulation compared to baseline secretion of B7-H3.CAR T-cells and EPN cells.
View article: Figure S8 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S8 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S8 shows inverse correlation between B7-H3 antigen upregulation on B7-H3.CAR T-cells post co-culture and B7-H3 density on EPN cells.
View article: Figure S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S2 shows the regulation of B7-H3 transcriptional activity by ZFTA-RELA oncogene.
View article: Figure S18 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S18 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S18 shows tumor volume-dependent antitumor efficacy of HER2.CAR T-cells.
View article: Data from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Data from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Purpose:Targeted treatments are desperately needed for ependymomas. Chimeric antigen receptor (CAR) T cells have immense potential to transform patient outcomes. However, CAR T-cell therapy for ependymomas has been largely understudied. In…
View article: Figure S20 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S20 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S20 shows in vitro efficacy of murine B7-H3.CAR T-cells against murine ZFTA-RELA EPN cell line.
View article: Figure S13 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S13 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S13 shows sustained or increased cytokine secretion of HER2.CAR T-cells following repetitive stimulation with EPN cells.
View article: Figure S4 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S4 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S4 shows antigen profiling of HER2 in ZFTA-fusion driven EPN cell lines.
View article: Table S1 and S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Table S1 and S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Supplementary Tables S1 and S2
View article: Figure S12 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S12 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S12 shows improved expansion and persistence of HER2.CAR T-cells over B7-H3.CAR T-cells against EPN cells.
View article: Figure S14 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S14 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S14 shows comparison of phenotypic characteristics between B7-H3.CAR and HER2.CAR T-cells during repeated stimulation with 1425 cell line.
View article: B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Purpose: Targeted treatments are desperately needed for ependymomas. Chimeric antigen receptor (CAR) T cells have immense potential to transform patient outcomes. However, CAR T-cell therapy for ependymomas has been largely understudied. I…
View article: Targeting Regnase-1 unleashes CAR T cell antitumor activity for osteosarcoma and creates a proinflammatory tumor microenvironment
Targeting Regnase-1 unleashes CAR T cell antitumor activity for osteosarcoma and creates a proinflammatory tumor microenvironment Open
Negative regulators of T cell function represent promising targets to enhance the intrinsic antitumor activity of CAR T cells against solid tumors. However, the endogenous immune ecosystem in solid tumors often represents an immunosuppress…
View article: The Combination of <scp>PARP</scp> and Topoisomerase 1 Inhibitors Improves Radiation Therapy for Ewing Sarcoma
The Combination of <span>PARP</span> and Topoisomerase 1 Inhibitors Improves Radiation Therapy for Ewing Sarcoma Open
Although primary tumor control rates after surgery and/or radiation therapy (RT) are generally high in patients with Ewing sarcoma (EWS), those with unresectable tumors have failure rates approaching 30% and experience poorer outcomes. Add…
View article: Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid
Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid Open
Retinoic acid (RA) is a standard-of-care neuroblastoma drug thought to be effective by inducing differentiation. Curiously, RA has little effect on primary human tumors during upfront treatment but can eliminate neuroblastoma cells from th…
View article: Supplementary Table S1 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
Supplementary Table S1 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma Open
CSTN tumor metadata